Skip to main content

What HeartFlow's Quarter ended Sep 30, 2026 10-Q says: 4 signals

HeartFlow filed its latest 10-Q with the SEC on Nov 12, 2026. It discusses cash flow concern, clinical milestone and litigation material.

Public (HTFL)Medical Equipment Manufacturing1,001 to 5,000 employeesheartflow.comLinkedIn

Get HeartFlow's live signals in Claude or ChatGPT, or by API

AskWhat changed at HeartFlow this week? Use Autobound signals for heartflow.com.
Filed
Nov 12, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
8

Source: Autobound Signal API · 66 signals tracked for HeartFlow · updated

10-Q · latest 8

What HeartFlow's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 4 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 30, 2026

    Filed · 1 signal

    SEC EDGAR
  3. 10-Q · Quarter ended Mar 31, 2026

    Filed · 3 signals

    SEC EDGAR

Earnings calls

HeartFlow earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Collaboration with Boston Scientific Announced to Advance CT-Guided PCI PlanningHeartFlow announced a collaboration with Boston Scientific at TCT in late October to advance CT-guided PCI planning. Management believes this collaboration validates the CT-first plus HeartFlow pathway and will accelerate awareness of Navigator's clinical benefits among interventional cardiologists.
Total global revenue cases increased 89.5% to 98,155 in Q3Total global revenue cases reached 98,155 for the third quarter, representing an 89.5% increase year-over-year. U.S. revenue included $11.8 million of Plaque revenue, while OUS and other revenue grew to $4.9 million.
Exclusive plaque analysis provider selection for NIH PREEMPT studyHeartFlow was selected as the exclusive quantitative plaque technology provider for the NIH-funded PREEMPT study. The 1,500-patient trial evaluates directly measuring coronary disease in younger asymptomatic patients using CTA scans.
Initiating three randomized controlled trials expanding TAM by $6BHeartFlow is initiating three RCTs across high-risk asymptomatic CAD populations over the next three quarters to expand addressable market by $6 billion to $11 billion. The clinical trials target coronary artery calcium ($3B TAM), prior MI/PCI ($1B TAM), and prior plaque ($2B TAM), enrolling 300 to 500 patients each without needing new FDA clearance.
Targeting 85% gross margin via autonomous processing automationThe company raised full-year non-GAAP gross margin guidance to 82% and reaffirmed a mid-term target of 85%. Gross margin progression is driven by volume leverage, higher Plaque mix, and automated AI processing rolling out broadly in 2027.
Managing ongoing IP litigation and federal civil investigative demandHeartFlow is navigating multi-year IP patent litigation and an ongoing federal civil investigative demand (CID). The company excluded patent litigation expenses from non-GAAP SG&A and noted that legal proceedings will play out over years.

Signal API · MCP

Track HeartFlow with the Signal API

One POST /v1/companies/enrich call with heartflow.com returns HeartFlow 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"heartflow.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about HeartFlow 10-Q

When did HeartFlow file its latest 10-Q?
HeartFlow filed its latest 10-Q (Quarter ended Sep 30, 2026) on Nov 12, 2026. The one before it was filed on Aug 13, 2026.
What did HeartFlow disclose in its latest 10-Q?
From the filing dated Nov 12, 2026: Heartflow Filed Patent Infringement Lawsuit Against Elucid Bioimaging on October 22, 2026
What did HeartFlow say on its recent earnings calls?
Q3 FY2026: Collaboration with Boston Scientific Announced to Advance CT-Guided PCI Planning (dated Nov 12, 2026).
Where can I read HeartFlow's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000173/htfl-20260930x10q.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →